Zanamivir® News 

Dihydropyrancarboxamides Related to Zanamivir: A New Series of...
Found on 19 Feb 2010 14:36 GMT

Tags Dihydropyrancarboxamides Related to Zanamivir: A New Series of Inhibitors of Influenza Virus Sialidases.

Simcere Wins OK for Flu Drug Relenza
Found on 13 Feb 2010 05:41 GMT

Simcere Pharmaceutical Group reported it has received SFDA approval to manufacture and market Relenza , the flu treatment developed by GlaxoSmithKline .

Simcere Receives SFDA Approval to Manufacture and Sell Zanamivir in China
Found on 12 Feb 2010 05:21 GMT

Simcere Pharmaceutical Group, a pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that one of its subsidiaries, Nanjing Simcere Dongyuan Pharmaceutical Co.

Biota Announces Relenza Royalty for December 2009 Quarter
Found on 05 Feb 2010 04:30 GMT

Biota Holdings Limited today announced that it had received written notification from GlaxoSmithKline that Relenza sales were $462 million and indicative royalties were $32.6 million, for the three months ended 31 December 2009.

Intravenous Zanamivir for Oseltamivir-Resistant 2009 H1N1 Influenza
Found on 24 Dec 2009 01:17 GMT

To the Editor: A 10-year-old girl with acute lymphoblastic leukemia was transferred to our hospital on August 31.

Impact of Zanamivir on Antibiotic Use for Respiratory Events...
Found on 20 Dec 2009 08:32 GMT

Background Influenza infections commonly lead to respiratory tract complications that result in antibiotic treatment.

Evidence on zanamivir (Relenza).
The National Institute of Clinical Excellence (NICE) has issued guidance to the NHS concerning the use of zanamivir in the treatment of influenza. It has also posted on its Internet site (www.nice.org.uk) a summary of the evidence used in making its decision

Publication: Bandolier

Biota Announces Zanamivir Will Enter Phase III Clinical Trials in May 1997
MELBOURNE, Australia, Feb. 24 /PRNewswire/ - Biota Holdings Limited (Australian Stock Exchange: BTA) today announced that Glaxo Wellcome p1c, the Company's development partner, has informed management that Phase III clinical trials of zanamivir, or GG167, for the treatment of influenza, planned to

Publication: PR Newswire

Transmission within Families Reduced with Zanamivir.
2000 NOV 21 - (NewsRx.com) - Families like to share a lot of things, but the flu shouldn't be one of them. A new study, published in the November 2, 2000, issue of the New England Journal of Medicine, found that zanamivir can prevent the flu from making the rounds within a family when one member

Publication: TB & Outbreaks Week

Drug to treat flu also protects against it.(zanamivir)(Brief Article)
For 3 decades, scientists have been experimenting with medications that stifle the influenza virus. Two drugs, amantadine and rimantadine, can impede the disease and limit symptoms. However, neither works against one of the two major strains of influenza, and both can be eluded by the evolving

Publication: Science News

Faster Relief from Influenza Symptoms for 'High Risk' and Otherwise Healthy P...
Clinical Trial Data Show Up to a 2.5-Day Reduction in Time to Alleviation of Symptoms of Influenza MELBOURNE, Australia, Nov. 17 /PRNewswire/ - Biota Holdings Limited has been advised by its development partner, Glaxo Wellcome (NYSE: GLX), that the results of two Phase III clinical trials of

Publication: PR Newswire

The cost effectiveness of zanamivir and oseltamivir for influenza treatment
ABSTRACT In this month's column, the authors evaluate the cost effectiveness of oseltamivir and zanamivir, compared with standard care, for the treatment of influenza. Using efficacy data from randomized, placebo-controlled clinical trials, a cost-effectiveness model was constructed. In an

Publication: Formulary

Inhaled Zanamivir Beats Rimantadine.
TORONTO - The new, inhaled anti-influenza drug, zanamivir, was more effective than rimantadine for preventing flu transmission in nursing homes in a head-to-head comparison. This finding "supports the use of zanamivir for institutional outbreak control," Dr. Stefan Gravenstein said at the annual

Publication: Family Practice News

Zanamivir provides effective influenza prophylaxis in exposed family members
San Francisco-The inhaled neuraminidase inhibitor zanamivir can prevent influenza acquisition within families, reported Frederick Hayden, MD. The drug, which recently received market clearance for the treatment of influenza, works by inhibiting the neuraminidase of both influenza A and B viruses.

Publication: Formulary

Zanamivir for Inhalation (Relenza-Glaxo Welcome).(Brief Article)
JUST IN TIME FOR THE 1999 FLU SEASON, THE FDA HAS approved Glaxo Wellcome's zanamivir (Relenza) for the treatment of influenza A and B. Zanamivir is the first of a new class of antiviral drugs, the sialic acid analogs, which were developed though computer-assisted design. These drugs are believed

Publication: Internal Medicine Alert

Zanamivir for Inhalation (Relenza-Glaxo Wellcome).
Pharmacology Update Zanamivir for Inhalation (RelenzaGlaxo Wellcome) By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD Just in time for the 1999 flu season, the fda has approved Glaxo Wellcomes zanamivir (Relenza) for the treatment of influenza A and B virus infections. Zanamivir is the

Publication: Infectious Disease Alert